Atossa Therapeutics Set to Be Included in the Russell 2000 and Russell 3000 Indexes
16 June 2021 - 11:00PM
Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage
biopharmaceutical company seeking to discover and develop
innovative medicines in areas of significant unmet medical need
with a current focus on breast cancer and COVID-19, today announced
it is set to be added to the Russell 2000 and Russell 3000 Indexes
This milestone will take place at the conclusion of the 2021
Russell Indexes’ annual reconstitution, effective after the U.S.
market opens on June 28, 2021, according to a preliminary list of
additions posted June 4, and June 14, 2021.
“Atossa’s inclusion in both the Russell 2000 and Russell 3000
Indexes present an important opportunity for us to further expand
Atossa’s awareness among a broader group of investors, which we
expect will also further enhance its liquidity,” said Kyle Guse,
Atossa’s CFO and General Counsel.
Membership in the Russell 2000 and Russell 3000 Indexes, which
remains in place for one year each, means automatic inclusion in
the appropriate growth and value style indexes. FTSE Russell
determines membership for its Russell Indexes primarily by
objective, market-capitalization rankings, and style
attributes.
Russell Indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $10.6 trillion in
assets are benchmarked against Russell’s U.S. Indexes. Russell
Indexes are part of FTSE Russell, a leading global index
provider.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical
company seeking to discover and develop innovative medicines in
areas of significant unmet medical need with a current focus on
breast cancer and COVID-19. For more information, please visit
www.atossatherapeutics.com.
Forward-Looking Statements Disclaimer
Statement
Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including,
without limitation, statements regarding the satisfaction of
closing conditions relating to the offering and the anticipated use
of proceeds from the offering, the risks and uncertainties
associated with any variation between interim and final clinical
results, actions and inactions by the FDA, the outcome or timing of
regulatory approvals needed by Atossa including those needed to
commence studies of AT-H201, AT-301 and Endoxifen, lower than
anticipated rate of patient enrollment, estimated market size of
drugs under development, the safety and efficacy of Atossa’s
products, performance of clinical research organizations and
investigators, obstacles resulting from proprietary rights held by
others such as patent rights, whether reduction in Ki-67 or any
other result from a neoadjuvant study is an approvable endpoint for
oral Endoxifen, and other risks detailed from time to time in
Atossa’s filings with the Securities and Exchange Commission,
including without limitation its periodic reports on Form 10-K and
10-Q, each as amended and supplemented from time to time.
Company Contact:Atossa Therapeutics, Inc.Kyle
Guse, CFO and General CounselOffice: 866
893-4927kyle.guse@atossainc.com
Investor Relations
Contact:Core IROffice:(516)
222-2560ir@atossainc.com
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Apr 2024 to May 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From May 2023 to May 2024